Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HPD | P32754 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25467506 | 0.70 | — | — | |
| SCHEMBL9972939 | 0.69 | KMT2A (0.42) | ADORA2BKMT2ARXFP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14803801 | 0.68 | LMNA (0.43) | KMT2ARXFP1ALDH1A1 | |
| SCHEMBL12157011 | 0.68 | ADORA2B (0.41) | ADORA2BKMT2ARXFP1HPDALDH1A1 | |
| SCHEMBL21787983 | 0.68 | ADORA2B (0.41) | ADORA2BHPDALDH1A1 | |
| SCHEMBL18512536 | 0.67 | ADORA2B (0.42) | ADORA2BKMT2ARXFP1HPDALDH1A1 | |
| SCHEMBL20045954 | 0.67 | KMT2A (0.39) | KMT2ARXFP1ALDH1A1 | |
| SCHEMBL18419738 | 0.63 | KDM5B (0.36) | SMN1; SMN2 | |
| SCHEMBL21500472 | 0.63 | ALDH1A1 (0.41) | ADORA2BALDH1A1 | |
| SCHEMBL2757599 | 0.63 | ADORA2B (0.38) | ADORA2BHPDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | ADORA2B 2885/4885KMT2A 2156/4885RXFP1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.